Nyhetsrum - PILA PHARMA | beQuoted Nyheter

Pressmeddelanden

2026-02-17 16:00

PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announced the outcome of exercise in warrants of...

2026-02-17 12:00

REG MAR

PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2 THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEA...

2026-02-12 12:00

REG

PILA PHARMA: Upcoming last days for exercise with the warrants of series TO2 THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEA...

2026-02-11 16:30

PILA PHARMA: CEO REPORT INTERVIEW AND Q&A ON CLINICAL PLANS, TO2 WARRANTS AND MORE, AVAILABLE FOR REPLAY NOW PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A. CEO Gustav...

2026-02-10 11:00

PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A. CEO Gustav...

2026-02-10 08:30

REG

PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2025. The report can be found on the Company´s website: https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025) • Operating i...

Visa fler pressmeddelanden